KRAS and cancer: Furthermore, the development of assay platforms thatcan identify selective inhibitors for mutants outside of G12C andG12D (for which multiple inhibitors have already been developed) willlead to a more tailored, personalized medicine approach for patientsharboring other KRAS mutations prevalent in various cancers.